As Managing Director on the Healthcare Practice Team, Chelsea Bolyard, PhD utilizes her experience in clinical, translational, and basic science to support client development of biomedical research programs and funding acquisition. With over ten years of research administration expertise, she supports clients by providing strategic and scientific guidance, which is bolstered by her skills in communication, project management, mentorship, stakeholder coordination, and interdisciplinary biomedical research.
Prior to joining McAllister & Quinn, Dr. Bolyard spent three years as the Associate Director for Research Communications within the Pelotonia Institute for Immuno-Oncology at The Ohio State University Comprehensive Cancer Center (OSUCCC). She was responsible for strategic planning, implementation, and program management of research operations supporting the Institute’s strategic plan. Before that, Chelsea spent two years as the Assistant Director in the Office of Programmatic Grants at OSUCCC wherein she supported the development, submission, and administration of programmatic grants (such as P01s, SPOREs), proposals to the NCI National Clinical Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN) (e.g., U54, U10, UM1), as well other large grants with complex structure issued by the NIH or other peer-reviewed funding agencies.
Dr. Bolyard has a history of publication in the fields of cancer biology, sex bias and immunology, oncolytic viruses/gene therapy, immuno-oncology and experimental therapeutics, and immune responses to mRNA vaccine in cancer patients. Her research can be found in high-impact journals such as J Clin Invest, Sci Immunol, Journal Immunother Cancer, J Hematol Oncol, Cancer Res, Clinical Cancer Res, and others.
Chelsea obtained her Bachelor of Arts in Microbiology & Zoology from Miami University (Ohio), with a minor in Criminology. She earned her Ph.D. in Biomedical Research with a focus on Cancer Biology & Experimental Therapetics from The Ohio State University, where her research focused on the use of oncolytic viral therapies and gene therapy approaches to treat preclinical models of ovarian cancer and glioblastoma. She resides in Columbus, Ohio.